| Combination Immunotherapy Targeting Sarcomas (NCT04433221) | Shenzhen Geno-Immune Medical Institute | 2026-07-01 |
| Engineered Immune Effectors Against Cervical Cancer (NCT03362619) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| PSMA-specific CAR-T Cell Therapy (NCT04429451) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| CD19/70 Bi-specific CAR-T Cell Therapy (NCT05436496) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| GD2/CD70 Bi-specific CAR-T Cell Therapy (NCT05438368) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276 (NCT04432649) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma (NCT03271632) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| CD19/22 Bi-specific CAR-T Cell Therapy (NCT05432882) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL (NCT05277753) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| Engineered Immune Effectors Against Ovarian Cancer (NCT03362606) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| CAR-T Cells Targeting Autoimmune Diseases (NCT05459870) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| 4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma (NCT04637503) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| CD19/79b Bi-specific CAR-T Cell Therapy (NCT05436509) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| 4SCAR-T Therapy Post CD19-targeted Immunotherapy (NCT04430530) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL (NCT05262673) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of HPV (NCT03351855) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections (NCT03159364) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| Intervention of CAR-T Against Cervical Cancer (NCT03356795) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| Immunity and Safety of Covid-19 Synthetic Minigene Vaccine (NCT04276896) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies (NCT04033302) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| FANCA Gene Transfer for Fanconi Anemia Using a High-safety, High-efficiency, Self-inactivating Lentiviral Vector (NCT03351868) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| GD2/PSMA Bi-specific CAR-T Cell Therapy (NCT05437315) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| PSMA/CD70 Bi-specific CAR-T Cell Therapy (NCT05437341) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| Universal CAR-T Cells Targeting AML (NCT05995041) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| 4SCAR19U T Cells Targeting B Cell Malignancies (NCT05995015) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis (NCT04085159) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| Safety and Immunity of Covid-19 aAPC Vaccine (NCT04299724) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| Multi-CAR-T Cells Targeting B Cell Lymphomas (NCT04429438) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| 4SCAR-CD44v6 T Cell Therapy Targeting Cancer (NCT04427449) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| GD2/CD56 Bi-specific CAR-T Cell Therapy (NCT05437328) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas (NCT03356782) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| Immune Modulatory DC Vaccine Against Brain Tumor (NCT03914768) | Shenzhen Geno-Immune Medical Institute | 2026-05-31 |
| H3K27M-specific Immune Effector Cells Targeting DMG/DIPG (NCT07501156) | Shenzhen Geno-Immune Medical Institute | 2026-03-18 |
| cfMSC Therapy for Diabetes (NCT07495956) | Shenzhen Geno-Immune Medical Institute | 2026-03-16 |
| Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors (NCT03393962) | Shenzhen Geno-Immune Medical Institute | 2025-12-01 |
| DLL3 CAR-T Therapy Targeting Brain Tumors (NCT07180927) | Shenzhen Geno-Immune Medical Institute | 2025-09-10 |
| NG2 and DLL3 CAR-T Cells Targeting Melanoma (NCT07193966) | Shenzhen Geno-Immune Medical Institute | 2025-09-01 |
| Combination Immunotherapy Targeting Melanoma (NCT06739226) | Shenzhen Geno-Immune Medical Institute | 2025-08-31 |
| IT and IV Lentiviral Gene Therapy for X-ALD (NCT03727555) | Shenzhen Geno-Immune Medical Institute | 2025-08-31 |
| Combination CAR-T Cell Therapy Targeting Hematological Malignancies (NCT03125577) | Shenzhen Geno-Immune Medical Institute | 2025-08-01 |
| Multiple CAR-T Cell Therapy Targeting AML (NCT04010877) | Shenzhen Geno-Immune Medical Institute | 2025-08-01 |
| Intervention of Bladder Cancer by CAR-T (NCT03185468) | Shenzhen Geno-Immune Medical Institute | 2025-08-01 |
| Multi-CAR T Cell Therapy for Acute Myeloid Leukemia (NCT03222674) | Shenzhen Geno-Immune Medical Institute | 2025-07-15 |
| CAR-T Immunotherapy Targeting CD19- ALL (NCT04016129) | Shenzhen Geno-Immune Medical Institute | 2025-07-15 |
| Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells (NCT03535246) | Shenzhen Geno-Immune Medical Institute | 2025-07-01 |
| Immunotherapy Treating GI Cancer (NCT03614650) | Shenzhen Geno-Immune Medical Institute | 2025-07-01 |
| Prostate Cancer Vaccines (NCT07068555) | Shenzhen Geno-Immune Medical Institute | 2025-06-15 |
| Lentiviral FVIII Gene Therapy (NCT03217032) | Shenzhen Geno-Immune Medical Institute | 2025-06-01 |
| Lentiviral FIX Gene Therapy (NCT03961243) | Shenzhen Geno-Immune Medical Institute | 2025-06-01 |
| Lentiviral Hematopoietic Stem Cell Gene Therapy for MLD (NCT07046338) | Shenzhen Geno-Immune Medical Institute | 2025-06-01 |
| Direct Lentiviral Injection Gene Therapy for MLD (NCT03725670) | Shenzhen Geno-Immune Medical Institute | 2025-05-31 |
| A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies (NCT03050190) | Shenzhen Geno-Immune Medical Institute | 2025-05-01 |
| Genetically Modified T Cells Against Ovarian Cancer (NCT03184753) | Shenzhen Geno-Immune Medical Institute | 2025-05-01 |
| Study on GD2 Positive Solid Tumors by 4SCAR-GD2 (NCT02992210) | Shenzhen Geno-Immune Medical Institute | 2025-05-01 |
| Clonal Fetal Mesenchymal Stem Cells (cfMSCs) for the Control of Immune-related Disorders (NCT03123458) | Shenzhen Geno-Immune Medical Institute | 2025-01-01 |
| Gene Therapy for ADA-SCID Using an Improved Lentiviral Vector (Ivlv-ADA) (NCT03645460) | Shenzhen Geno-Immune Medical Institute | 2024-06-30 |
| SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection (NCT03217617) | Shenzhen Geno-Immune Medical Institute | 2024-06-30 |
| Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells (NCT06435897) | Shenzhen Geno-Immune Medical Institute | 2024-05-15 |
| Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma (NCT06429150) | Shenzhen Geno-Immune Medical Institute | 2024-05-11 |
| Engineered Dendritic Cell Vaccines for Multiple Myeloma (NCT06435910) | Shenzhen Geno-Immune Medical Institute | 2024-05-11 |
| Universal CAR-T Cells Targeting Multiple Myeloma (NCT06006741) | Shenzhen Geno-Immune Medical Institute | 2023-10-31 |
| Universal 4SCAR7U Targeting CD7-positive Malignancies (NCT05995028) | Shenzhen Geno-Immune Medical Institute | 2023-10-31 |
| Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector (NCT03351829) | Shenzhen Geno-Immune Medical Institute | 2017-12-01 |
| Intervention of Engineered Immune Effector T Cells Against Lung Cancer (NCT03353428) | Shenzhen Geno-Immune Medical Institute | 2017-11-15 |